Skip to content

Assessment of Clinical Efficacy of Metronomic Capecitabine among Breast Cancer Patients

Assessment of Clinical Efficacy of Metronomic Capecitabine among Breast Cancer Patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
PACTR
Registry ID
PACTR202502755674107
Enrollment
200
Registered
2025-02-03
Start date
2020-01-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

standered of care

Sponsors

suez canal university hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: included female adults diagnosed with non-metastatic invasive breast cancer and had received their standard treatment and were: 1) Triple-negative breast cancer (TNBC) or , 2) Hormonal receptor positive /HER2neu negative if locally advanced &/or had high-risk pathological features. ?whose age range from (18 -80)

Exclusion criteria

Exclusion criteria: 1) Patients positive for Human Epidermal Growth Factor-2 (HER-2) subtype of breast cancer, 2) Patients scored > 2 on the Eastern Cooperative Oncology Group (ECOG) performance status scale . 3) Patients with any medical condition that could interfere with chemotherapy administration .

Design outcomes

Primary

MeasureTime frame
2 year disease free survival calculated fromthedateofstudyentry until time of development of local or/& distant metastasis.

Secondary

MeasureTime frame
overall survival measured from the time of participation in the study until the last follow up visit or death.

Countries

Egypt

Contacts

Public ContactFifi Elasyed

assistant professor of clinical oncology at suez canal university

fifimostafa@gmail.com01028278685

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026